Post job

CooperVision main competitors are Biomérieux, Alcon, and Bio-Techne.

Competitor Summary. See how CooperVision compares to its main competitors:

  • Alcon has the most employees (20,001).
  • Employees at Biomérieux earn more than most of the competitors, with an average yearly salary of $62,385.
Work at CooperVision?
Share your experience

CooperVision vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1958
4.4
San Ramon, CA9$1.1B25
1853
4.7
Rochester, NY7$4.8B12,000
1992
4.6
Draper, UT1$237.0M1,135
1985
4.5
Mentor, OH30$5.1B12,000
1945
4.8
Fort Worth, TX1$9.9B20,001
Enzymedica
1998
3.9
Venice, FL1$182.0M20
2003
4.2
Orlando, FL1$21.0M248
Mediatech
-
3.6
Manassas, VA1$380,0006
1967
4.4
Orange, CA1$110.0M280
1869
4.6
Lynchburg, VA1$200.0M750
1885
4.5
Elyria, OH1$741.7M3,400
1982
4.2
Lansing, MI3$924.2M1,764
1985
4.7
Weston, MA9$409.4M1,125
1995
4.1
West Caldwell, NJ1$6.3M75
1870
4.5
Bohemia, NY3$90.6M50
1963
4.7
Durham, NC1-6,828
1976
4.5
Minneapolis, MN5$1.2B2,250
1985
3.5
Orange, CA1$670,00050
1976
4.6
Waltham, MA2$1.4B3,000
1986
4.6
Exeter, PA1$350.0M1,000
1994
4.4
Centennial, CO1$21.4M420

Rate CooperVision's competitiveness in the market.

Zippia waving zebra

CooperVision salaries vs competitors

Among CooperVision competitors, employees at Biomérieux earn the most with an average yearly salary of $62,385.

Compare CooperVision salaries vs competitors

CompanyAverage salaryHourly salarySalary score
CooperVision
$44,554$21.42-
Bausch + Lomb
$58,260$28.01-
1-800 Contacts
$42,760$20.56-
Steris
$56,528$27.18-
Alcon
$60,684$29.18-
Enzymedica
$44,247$21.27-

Compare CooperVision job title salaries vs competitors

CompanyHighest salaryHourly salary
CooperVision
$32,613$15.68
Alcon
$39,690$19.08
Bausch + Lomb
$38,216$18.37
Biomérieux
$37,161$17.87
Invacare
$34,600$16.63
Metrex
$33,230$15.98
Neogen
$33,031$15.88
Pride Mobility Products
$32,858$15.80
Steris
$32,563$15.66
Smiths Medical - Wallace
$32,533$15.64
Bio-Techne
$32,514$15.63
Sartorius
$32,452$15.60
1-800 Contacts
$32,430$15.59
AlloSource
$32,324$15.54
Mediatech
$32,236$15.50
Nova Biomedical
$32,135$15.45
Enzymedica
$32,030$15.40
XYMOGEN
$32,023$15.40
Novel Ingredients
$32,002$15.39
C.B. Fleet
$31,973$15.37

Do you work at CooperVision?

Does CooperVision effectively differentiate itself from competitors?

CooperVision jobs

CooperVision demographics vs competitors

Compare gender at CooperVision vs competitors

Job titleMaleFemale
Bio-Techne47%53%
Neogen52%48%
1-800 Contacts56%44%
CooperVision56%44%
Alcon59%41%
Invacare64%36%
Male
Female

Compare race at CooperVision vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
51%28%9%8%4%
9.7
72%7%5%13%2%
9.1
65%15%10%8%3%
9.8
72%8%9%9%2%
8.4
77%10%2%6%4%
9.4
52%20%13%12%4%
9.9

CooperVision and similar companies CEOs

CEOBio
Charles R. Kummeth
Bio-Techne

Charles Kummeth is a Board Member at DHR International, Board Member at BSN Medical, and Board Member at Gentherm and is based in Lake Elmo, Minnesota. He has worked as Board Member at SPARTON CORP, President/CEO at BIO-TECHNE CORP, and President Mass Spectrometry and Chromatography division at Thermo Fisher Scientific. Charles attended University of North Dakota between 1978 and 1983, Carlson School of Management between 1991 and 1993, and University of St. Thomas between 1987 and 1989.

Matthew E. Monaghan
Invacare

Matthew E. Monaghan is an independent director who joined the Board in October 2016, and is a member of the Audit Committee and Nominating and Corporate Governance Committee. Mr. Monaghan currently serves as President and Chief Executive Officer at Invacare Corporation (NYSE:IVC) (“Invacare”), a medical device manufacturer for the home and long-term healthcare markets, a position he has held since April 2015. Mr. Monaghan was named Chairman of the Invacare Board in May 2015. He previously served as Senior Vice President, Global Hips and Reconstructive Research for Zimmer Biomet Holdings, Inc. (formerly known as Zimmer Holdings, Inc.) (“Zimmer”), a global company that designs, develops, manufactures and markets orthopedic reconstructive, spinal and trauma devices, dental implants, and related surgical products from 2014 to 2015. Mr. Monaghan also has served as Operating Executive for Texas Pacific Group from 2006 to 2009 and at Cerberus Capital Management from 2003 to 2005. He started his career with 13 years in the aerospace, medical and other industrial businesses of General Electric. Mr. Monaghan is a trustee of Cleveland Clinic Avon Lake Hospital. Mr. Monaghan was a member of the board of directors of CD Diagnostics, Inc. from 2012 to 2016 and served as the chairman of the Audit Committee from 2012 to 2015 and as chairman of the board from 2015 to 2016. He holds a Bachelor’s degree in Mechanical Engineering from Cornell University, a Master’s degree in Mechanical Engineering from MIT and an MBA from INSEAD Business School in France.

John E. Adent
Neogen

John Adent is a Board Member at NEOGEN CORP and President/CEO at NEOGEN CORP and is based in Lansing, Michigan. He has worked as Chief Executive Officer at ANIMAL HEALTH HOLDINGS, INC. and Pres & CEO:Animal Health at PATTERSON COMPANIES, INC.. John studied at DEPAUW UNIVERSITY between 1986 and 1990.

John Graham
1-800 Contacts

David J. Endicott
Alcon

David J. Endicott is the CEO of Alcon, a member of its Board of Directors, and leads the Alcon Executive Committee. He joined Alcon in July of 2016 as Chief Operating Officer. Prior to Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. During his tenure there, he led Hospira’s medical device business through a turnaround, carve-out, and eventual sale. Critical to the turnaround, he advanced the company’s product pipeline, returned its products to market from quality disruptions and accelerated global growth. Before joining Hospira, David served as an officer and executive committee member of Allergan where he spent more than 25 years of his career in leadership roles across Europe, Asia, Latin America and the US. He accelerated Allergan’s international growth and successfully built new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and aesthetic medicine. He currently serves on the Board of Directors of AdvaMed, and has previously served on the Boards of Zeltiq (NASDAQ: ZLTQ), and Orexigen (NASDAQ: OREX). David holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School.

Joseph C. Papa
Bausch + Lomb

Alexandre Mérieux
Biomérieux

Scott Meuser is a Chairman and Chief Executive Officer at Pride Mobility Products Corp and is based in United States. She works or has worked at Pride Mobility Products Corp.

Walter M Rosebrough Jr.
Steris

Walter M Rosebrough, age 65, director and President and Chief Executive Officer since October 2007. From February 2005 to September 2007, Mr. Rosebrough served as President and Chief Executive Officer of Coastal Hydraulics, Inc., a hydraulic and pneumatic systems company he purchased in 2005, and he continues to serve on its board of directors. Previously, Mr. Rosebrough spent nearly 20 years in the healthcare industry in various roles as a senior executive with Hill-Rom Holdings, Inc. (at the time, Hillenbrand Industries, Inc.), a worldwide provider of medical equipment and related services, including President and Chief Executive Officer of Support Systems International and President and Chief Executive Officer of Hill-Rom. Mr. Rosebrough is a director of Varex Imaging Corp.

Gordon Cohen
Pentron

CooperVision competitors FAQs

Search for jobs